Amgen's Leah Christl makes the case to keep the interchangeability designation for biosimilars
Amgen and its portfolio of 11 biosimilars is standing behind interchangeability, saying the designation should not be rescinded and that the FDA needs to retain …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
